Supplier
Nextron Medical Technologies INC.
Nextron Medical Technologies INC. was paid $15.42M by Medicaid between Jan 2018 and Nov 2024, across 12 billing codes. Its largest line is J1745, Injection, infliximab, excludes biosimilar, 10 mg — 48% of everything it billed.
33Billing provider infoNEXTRON MEDICAL TECHNOLOGIES INC.
TOTOWA, NJ 07512
TOTOWA, NJ 07512
33aNPI1053412643assigned 09/26/2006
33bProvider typeMedical Foods Supplier
28Total paid$15.42M
24GClaims35,256
24DCodes billed12
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,987 | $1.39M | |
| 2019 | 2,634 | $2.25M | |
| 2020 | 3,471 | $2.17M | |
| 2021 | 5,485 | $3.25M | |
| 2022 | 7,308 | $3.25M | |
| 2023 | 8,199 | $2.29M | |
| 2024incomplete | 6,172 | $805K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 48% | 1,510 | 1,402 | $7.46M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 28% | 845 | 659 | $4.27M |
| 99601 | 8.0% | 16,875 | 10,263 | $1.23M | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 7.1% | 464 | 401 | $1.10M |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 2.9% | 253 | 231 | $448K |
| 99602 | Nursing care in home rn | 1.9% | 4,931 | 4,138 | $294K |
| S9500 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | 1.6% | 1,376 | 431 | $245K |
| S9379 | Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | 1.5% | 5,052 | 4,461 | $227K |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 1,189 | 165 | $72K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 2,076 | 1,498 | $38K |
| S9359 | Home infusion therapy, anti-tumor necrosis factor intravenous therapy; (e.g., infliximab); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 643 | 604 | $32K |
| S9502 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 42 | 12 | $12K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKATEN, ALEX (CFO)
Parent organizationAMERITA, INC.
| Provider | Location | Paid |
|---|---|---|
| Amerita of New York, LLC. | New Hyde Park, NY | $8.08M |
| Amerita South Atlantic LLC | Apex, NC | $911K |
| Amerita South Atlantic LLC | High Point, NC | $727K |
| I V Solutions, INC. | Nashville, TN | $396K |
| Alternacare Infusion Pharmacy INC | Lenexa, KS | $366K |
| Amerita South Atlantic LLC | Kingsport, TN | $253K |
| Central Line Infusion Dallas Division LTD | Irving, TX | $109K |
| Amerita South Atlantic LLC | Charlotte, NC | $80K |
| Alternacare Infusion Pharmacy INC | Lenexa, KS | $5K |
| Central Line Infusion, LTD | Amarillo, TX | $166.11 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.